Menarini Spain and Takeda Pharmaceutical Spain signed a collaboration agreement in Barcelona to exclusively promote three new drugs for the treatment of type II diabetes in the country.
It is Vipidia (alogliptin) Vipdomet (Alogliptin and metformin) and Incresync (Alogliptin and pioglitazone). All cThey contain the new active ingredient alogliptin, which is indicated to improve glycemic control in combination with other hypoglycemic drugs, diet and exercise in adult patients with type II diabetes, whose blood sugar is not adequately controlled with previous treatments.
Under the terms of the agreement, Menarini will have exclusive rights to promote and inform the scientific and medical community of the three drugs, while Takeda will distribute them.
Wednesday, November 11, 2015 – El GlobalNet
Related news: Healthcare: dear Lorenzin, why don't you want to save money?
Diabetes: Italian patients doubled in 30 years and 15 billion in costs for the NHS
